Abstract
We recently demonstrated that endoxifen (4-hydroxy-N-desmethyl-tamoxifen), a pharmacogenetically regulated metabolite of tamoxifen, is equipotent to 4-hydroxy-tamoxifen (4-OH-Tam) with respect to estrogen receptor binding and inhibition of 17β-estradiol (E2)-induced cell proliferation. Endoxifen was also found to be more abundant in human plasma than 4-OH-Tam, and its formation has been shown to be primarily catalyzed by cytochrome P450 2D6 (CYP2D6). Here, we report studies evaluating the effects of endoxifen, 4-OH-Tam, and E2 on gene expression in MCF-7 cells using Affymetrix U133A GeneChip Arrays (Santa Clara, CA). We detected 4062 genes that were E2-regulated (1924 induced; 2138 suppressed), and the ratio of E2-induced versus E2-suppressed genes was consistent regardless of the cutoff value. In the presence of E2, 2444 and 2390 genes were affected by 4-OH-Tam and endoxifen, respectively, when no minimal -fold change cutoff was implemented. The majority of genes regulated by the tamoxifen metabolites were also E2-responsive (74.4 and 73.3%, respectively). Endoxifen and 4-OH-Tam had overlapping effects on 1365 E2-sensitive genes, whose -fold effects between these metabolites were highly correlated (R2 = 0.99). A significant correlation was also found between the -fold effects of 249 E2-insensitive genes coregulated by both metabolites (R2 = 0.99). Hierarchical clustering analysis demonstrated similar gene regulation patterns between these metabolites, which were distinct from E2 or vehicle treatment patterns. Using real time-polymerase chain reaction, we validated the gene expression patterns of five genes that were differentially regulated by endoxifen and 4-OH-Tam. We conclude that endoxifen and 4-OH-Tam have similar effects on global gene expression patterns in MCF-7 cells and that the majority of the affected genes are estrogen-regulated genes.
Footnotes
-
This study was supported in part by Pharmacogenetics Research Network Grants 2U-01 GM61373 (to D.A.F.) and K24RR020815 (to D.A.F.), National Institutes of Health Clinical Pharmacology Training Grant 5T32-GM-08425 (to D.A.F.), the Indiana University Center for Medical Genomics Core Facility, a grant of the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A050174; to Y.C.L.) and a grant from the Basic Research Program of the Korean Science and Engineering Foundation (R01-2006-000-11087-0; to Y.C.L.).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.105.100511.
-
ABBREVIATIONS: SERM, selective estrogen receptor modulator; endoxifen, 4-hydroxy-N-desmethyl-tamoxifen, IMEM, improved minimum essential medium; PharmGKB, the Pharmacogenetics and Pharmacogenomics Knowledge Base; E2, estradiol; PCR, polymerase chain reaction; GO, gene ontology; ER, estrogen receptor; 4-OH-Tam, 4-hydroxy-tamoxifen.
- Received December 22, 2005.
- Accepted May 9, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|